Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine SR in Adult Outpatients With Major Depressive Disorder
NCT00277823Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desvenlafaxine in major depressive disorder (MDD) (3 arms), sponsored by Pfizer. Primary endpoints: Antidepressant Efficacy, Safety and 1 more. Started Feb 2006; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00277823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00277823.